| Literature DB >> 23056143 |
Xueqiang Huang1, Qunwei Chen, Genjin Yang, Weixing Dai, Qingbo Lang, Juan Du, Shikai Yan, Weidong Zhang, Changquan Ling.
Abstract
This study proposes a (1)H NMR-based metabonomic approach to explore the biochemical characteristics of Yang deficiency syndrome in hepatocellular carcinoma (HCC) based on serum metabolic profiling. Serum samples from 21 cases of Yang deficiency syndrome HCC patients (YDS-HCC) and 21 cases of non-Yang deficiency syndrome HCC patients (NYDS-HCC) were analyzed using (1)H NMR spectroscopy and partial least squares discriminant analysis (PLS-DA) was applied to visualize the variation patterns in metabolic profiling of sera from different groups. The differential metabolites were identified and the biochemical characteristics were analyzed. We found that the intensities of six metabolites (LDL/VLDL, isoleucine, lactate, lipids, choline, and glucose/sugars) in serum of Yang deficiency syndrome patients were lower than those of non-Yang deficiency syndrome patients. It implies that multiple metabolisms, mainly including lipid, amino acid, and energy metabolisms, are unbalanced or weakened in Yang deficiency syndrome patients with HCC. The decreased intensities of metabolites including LDL/VLDL, isoleucine, lactate, lipids, choline, and glucose/sugars in serum may be the distinctive metabolic variations of Yang deficiency syndrome patients with HCC. And these metabolites may be potential biomarkers for diagnosis of Yang deficiency syndrome in HCC.Entities:
Year: 2012 PMID: 23056143 PMCID: PMC3463959 DOI: 10.1155/2012/843048
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Basic clinical feature of hepatocellular carcinoma patients with different syndrome.
| Group | Number ( | Gender ( | Age ( | HCC clinical staging ( | Child-Pugh grading ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Ia | Ib | IIa | IIb | IIIa | IIIb | A | B | C | |||
| YDS-HCC | 21 | 18 | 3 | 55.76 ± 12.79 | 3 | 0 | 1 | 4 | 11 | 2 | 14 | 5 | 2 |
| NYDS-HCC | 21 | 19 | 2 | 58.10 ± 7.31 | 3 | 1 | 1 | 6 | 9 | 1 | 14 | 6 | 1 |
HCC: hepatocellular carcinoma; YDS: Yang deficiency syndrome; NYDS: non-Yang deficiency syndrome.
Figure 1Representative 1H NMR spectra of serum from YDS-HCC patients (A) and NYDS-HCC patients (B); LDL, low-density lipid; VLDL, very low-density lipid.
Figure 2Results after PLS-DA using the 1H NMR spectra of serum from HCC patients. (a) PLS-DA score plot shows a clear separation between Yang deficiency syndrome patients with HCC (YDS-HCC) (■) and non-Yang deficiency syndrome patients with HCC (NYDS-HCC) (▲). (b) Examination of the corresponding loading plot indicated that those variances out of the ellipse were responsible for the separation of YDS-HCC and NYDS-HCC patients marked with chemical shift (ppm).
Assignment and intensities of metabolites in serum responsible for PLS-DA separation between YDS-HCC and NYDS-HCC patients.
| Metabolite |
| Assignment | Multiplicityb | Intensityc (103) |
| |
|---|---|---|---|---|---|---|
| YDS-HCC | NYDS-HCC | |||||
| LDL/VLDL | 0.84, 0.92, 1.24, 1.28, 1.32 | CH3(CH2) | m | 67.23 ± 32.64 | 115.66 ± 47.33 | 0.000 |
| Isoleucine | 0.96 |
| t | 8.27 ± 3.86 | 13.57 ± 6.20 | 0.002 |
| Lactate | 1.36, 1.40 | CH3 | d | 19.44 ± 15.19 | 53.44 ± 25.92 | 0.000 |
| Lipids | 2.00, 2.04 | CH2C=C | m | 9.45 ± 3.73 | 13.89 ± 5.04 | 0.002 |
| Choline | 3.24 | N(CH3)3 | s | 10.23 ± 5.53 | 16.05 ± 9.04 | 0.016 |
| Glucose/sugars | 3.28, 3.40, 3.44, | Various | m | 46.05 ± 27.74 | 68.39 ± 40.92 | 0.045 |
HCC: hepatocellular carcinoma; YDS: Yang deficiency syndrome; NYDS: non-Yang deficiency syndrome; PLS-DA: partial least square discriminatory analysis; LDL: low-density lipid; VLDL: very low-density lipid.
aChemical shifts were reported with reference to 3-trimethylsilylpropanesulfonate (TPS) singlet resonance at 0.000 ppm.
bMultiplicity: s: singlet; d: doublet; t: triplet; m: multiplet.
cData are expressed as mean ± SD.
d P value calculated by Mann-Whitney U test or t test.